Evidence map›Paper›PMID 26911368›Full record

ArticleBMC biotechnology2016

Generating aldehyde-tagged antibodies with high titers and high formylglycine yields by supplementing culture media with copper(II).

Dona York, Jeanne Baker, Patrick G Holder, Lesley C Jones, Penelope M Drake, Robyn M Barfield, Gregory T Bleck, David Rabuka

Open access · goldAbstract read
In one paragraph

Article in BMC biotechnology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
6.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 46 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Arylation Chemistry for Bioconjugation.Angewandte Chemie (International ed. in English) · 2019
    Review
  10. Formylglycine-generating enzyme binds substrate directly at a mononuclear Cu(I) center to initiate OProceedings of the National Academy of Sciences of the United States of America · 2019
    Article
  11. Article
  12. Current Conjugation Methods for Immunosensors.Nanomaterials (Basel, Switzerland) · 2018
    Review
  13. Review
  14. Article
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Dona YorkCatalent Pharma Solutions, 726 Heartland Trail, Madison, WI, 53717, USA. dona.york@catalent.com.
Jeanne BakerCatalent Pharma Solutions, 5703 Hollis Street, Emeryville, CA, 94608, USA. jeannebaker2010@gmail.com.
Patrick G HolderCatalent Pharma Solutions, 5703 Hollis Street, Emeryville, CA, 94608, USA. pgholder@gmail.com.
Lesley C JonesCatalent Pharma Solutions, 5703 Hollis Street, Emeryville, CA, 94608, USA. jones.lesleyc@gmail.com.
Penelope M DrakeCatalent Pharma Solutions, 5703 Hollis Street, Emeryville, CA, 94608, USA. penelope.drake@catalent.com.
Robyn M BarfieldCatalent Pharma Solutions, 5703 Hollis Street, Emeryville, CA, 94608, USA. robyn.barfield@catalent.com.
Gregory T BleckCatalent Pharma Solutions, 726 Heartland Trail, Madison, WI, 53717, USA. gregory.bleck@catalent.com.
David RabukaCatalent Pharma Solutions, 5703 Hollis Street, Emeryville, CA, 94608, USA. david.rabuka@catalent.com.
Catalent (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe ability to site-specifically conjugate a protein to a payload of interest (e.g., a fluorophore, small molecule pharmacophore, oligonucleotide, or other protein) has found widespread application in basic research and drug development. For example, antibody-drug conjugates represent a class of biotherapeutics that couple the targeting specificity of an antibody with the chemotherapeutic potency of a small molecule drug. While first generation antibody-drug conjugates (ADCs) used random conjugation approaches, next-generation ADCs are employing site-specific conjugation. A facile way to generate site-specific protein conjugates is via the aldehyde tag technology, where a five amino acid consensus sequence (CXPXR) is genetically encoded into the protein of interest at the desired location. During protein expression, the Cys residue within this consensus sequence can be recognized by ectopically-expressed formylglycine generating enzyme (FGE), which converts the Cys to a formylglycine (fGly) residue. The latter bears an aldehyde functional group that serves as a chemical handle for subsequent conjugation.

resultsThe yield of Cys conversion to fGly during protein production can be variable and is highly dependent on culture conditions. We set out to achieve consistently high yields by modulating culture conditions to maximize FGE activity within the cell. We recently showed that FGE is a copper-dependent oxidase that binds copper in a stoichiometric fashion and uses it to activate oxygen, driving enzymatic turnover. Building upon that work, here we show that by supplementing cell culture media with copper we can routinely reach high yields of highly converted protein. We demonstrate that cells incorporate copper from the media into FGE, which results in increased specific activity of the enzyme. The amount of copper required is compatible with large scale cell culture, as demonstrated in fed-batch cell cultures with antibody titers of 5 g · L(-1), specific cellular production rates of 75 pg · cell(-1) · d(-1), and fGly conversion yields of 95-98 %.

conclusionsWe describe a process with a high yield of site-specific formylglycine (fGly) generation during monoclonal antibody production in CHO cells. The conversion of Cys to fGly depends upon the activity of FGE, which can be ensured by supplementing the culture media with 50 uM copper(II) sulfate.

Indexed as

AldehydesAnimalsAntibodiesCHO CellsCopperCricetinaeCricetulusCulture MediaGlycineAldehydesAntibodiesCopperCulture MediaGlycine

Identifiers

PMID26911368
PMCPMC4766608
OpenAlexW2274736795

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.